Valeant receives European Commission marketing authorization for Trobalt

Download PDF Copy

Mar 30 2011

“This is a milestone for retigabine and our partnership with Valeant”

Meda's (STO:MEDAA) partner for retigabine, Valeant Pharmaceuticals International, Inc., today announced that the European Commission has granted the marketing authorization for Trobalt™ (retigabine) in the epilepsy therapy area.

"This is a milestone for retigabine and our partnership with Valeant", said Anders Lönner, CEO Meda AB.

Valeant has a collaboration agreement with the pharmaceutical company GlaxoSmithKline for the global commercialization of retigabine. Meda is entitled to receive royalties of between 6 - 8 percent on retigabine sales.

Source:

MEDA AB

Posted in: Medical Condition News | Pharmaceutical News

Tags: Epilepsy, GlaxoSmithKline, Pharmaceuticals

Comments (0)

Download PDF Copy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.